ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

antihemophilic factor, human recombinant

Also written as “Antihemophilic factor, recombinant, manufactured protein-free”, “Recombinant Factor VIII (BAY81-8973)” and “ADVATE”.

Its studies are mostly in Hemophilia A · von Willebrand Diseases, led by 3 companies.

Drug pageAntihemophilic factor, human recombinant: every studyAll 23 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Oct 21, 200516 company-led studies, 1 open or runningNext primary completion: Nov 25, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takedaits history only101 open or runningphase 4since Oct 21, 2005Sep 8, 2005Nov 25, 2027phase 3 · NCT07129343
Bayer50 open or runningphase 4since Sep 4, 2020Dec 8, 2009none ahead
Novo Nordiskits history only10 open or runningphase 1since Feb 4, 2009Feb 4, 2009none ahead

Also a collaborator on its studies: Takeda Development Center Americas and Baxter Innovations.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Bayer only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 8, 2009First study: phase 3 study in Blood Coagulation DisordersFirst studyNCT01029340 · 74 enrolled · United States, Argentina, Austria and more
  2. Nov 2, 2010Phase 3 study in Hemophilia ANCT01233258 · 80 enrolled · United States, Argentina, China and more
  3. Feb 18, 2011Phase 3 study in Hemophilia ANCT01311648 · 94 enrolled · United States, Argentina, Bulgaria and more
  4. Jun 24, 2015Phase 1 study in Hemophilia ANCT02483208 · 18 enrolled · Bulgaria
  5. Sep 4, 2020Phase 4 study in Hemophilia ANCT04565236 · 45 enrolled · China
  6. Oct 21, 2026Primary completion moved from 2027-09-30 to 2028-03-31Date moved laterno phase · +6 months · NCT07446010

TargetBeta

F8 →read by rule
“Coagulation factor VIII exogenous protein”ChEMBL 37, by rule

Other programs on F8

ProgramCompanyFurthest phaseStudies
efanesoctocog alfaruleSanofiphase 412
omfiloctocog alfaruleSinocelltech Groupphase 46
lonoctocog alfaruleCSLphase 34

Studies

All 5 Bayer leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04565236Hemophilia A · China4CompletedMar 15, 202445
NCT02483208Hemophilia A · Bulgaria1CompletedJul 201518
NCT01311648Hemophilia A · United States, Argentina, Bulgaria and more3CompletedSep 9, 201994
NCT01233258Hemophilia A · United States, Argentina, China and more3CompletedDec 201280
NCT01029340Blood Coagulation Disorders · United States, Argentina, Austria and more3CompletedJun 201274

How it is read

Names in the registry

  • “Antihemophilic factor, recombinant, manufactured protein-free”, 8 entries
  • “Recombinant Factor VIII (BAY81-8973)”, 3 entries
  • “ADVATE”, 2 entries
  • “Recombinant Factor VIII (Kovaltry, BAY81-8973)”, 2 entries
  • “Antihemophilic Factor (Recombinant)”, 1 entry

Codes read as this program: BAY818973.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.